The present invention relates to relates to a pharmaceutical composition comprising butein (BTN) and sulfuretin (SLF) and/or isoliquiritigenin (ILQ), or pharmaceutically acceptable salts, tautomers, solvates and/or derivatives thereof. The invention further relates to the use of said compositions in the treatment of diabetes or an associated disease, condition and/or disorder such as prediabetes and/or diet-induced impairment of glucose regulation, and the use of compositions comprising sulfuretin (SLF) or isoliquiritigenin (ILQ) alone for said treatments.
